CYP3A4 and ovarian cancer: ● CYP3A4/3A5 - Among 261 European patients with ovarian cancer treated with paclitaxel and platinum as first-line chemotherapy, the carriers of the CYP3A4*1B G allele were found to have inferior survival rates as compared with those showing the AA genotype, probably as result of the higher detoxifying activity of the CYP3A4*1B G isoform [151].